Development of 1‐(2‐aminophenyl)pyrrole‐based amides acting as human topoisomerase I inhibitors

Author:

Carullo Gabriele1ORCID,Mazzotta Sarah2ORCID,Ceramella Jessica3,Iacopetta Domenico3,Ramunno Anna4,Rosano Camillo5ORCID,Brizzi Antonella1,Campiani Giuseppe1ORCID,Aiello Francesca3ORCID,Sinicropi Maria S.3

Affiliation:

1. Dipartimento di Biotecnologie, Chimica e Farmacia Università degli Studi di Siena Siena Italy

2. Dipartimento di Chimica Università degli Studi di Milano Milano Italy

3. Dipartimento di Farmacia e Scienze della Salute e della Nutrizione Università della Calabria Rende Italy

4. Dipartimento di Farmacia Università degli Studi di Salerno Fisciano Italy

5. Unità di Proteomica e Spettrometria di Massa IRCCS Ospedale Policlinico San Martino Genova Italy

Abstract

AbstractTopoisomerases are ubiquitous enzymes in the human body, particularly involved in cancer development and progression. Topoisomerase I (topoI) performs DNA relaxation reactions by “controlled rotation” rather than by “strand passage.” The inhibition of topoI has become a useful strategy to control cancer cell proliferation. Nowadays, different compounds have undergone clinical trials, but the search for new molecular entities is necessary and benefits from medicinal chemistry efforts. Pyrrole‐based compounds emerged as promising antiproliferative agents, with particular interest in breast cancer therapy and topoI inhibition. Starting from these observations and based on the scaffold‐hopping approach, we developed a small library of 1‐(2‐aminophenyl)pyrrole‐based amides (7a–f) as new anticancer agents. Tested on a panel of cancer cell lines, 7a–f displayed the most interesting profile in MDA‐MB‐231 cells, where the most active compounds, 7d–f, were able to induce death by apoptosis. Direct enzymatic assays and docking simulations on the topoI active site (PDB: 1A35) revealed the inhibitory activity and potential binding site for the newly developed 1‐(2‐aminophenyl)pyrrole‐based amides.

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3